Menu
  
  

American Conference Institute’s 11th Summit on Biosimilars & Innovator Biologics

Members of Paul Hastings’ Intellectual Property Litigation Practice are proud to speak at ACI’s Biosimilars and Innovator Biologics conference, taking place on September 23-24, 2020 in Boston and virtually. The conference focuses on recent developments in litigation and regulations surrounding biosimilars and innovator biologics, and features invited speakers from the FDA, the PTAB, and companies including Amgen Inc., Apotex Inc., Baxter Healthcare Corporation, Biocon Biologics, Eisai Inc., Fosun Pharma, Fresenius Kabi, Hikma Pharmaceutical, Teva, and more. Eric W. Dittmann, Partner and Global Vice Co-Chair, Intellectual Property Practice, will participate on a panel “Key Litigations and Decisions at the Federal Circuit, the District Courts and the PTAB.” Isaac S. Ashkenazi, Partner, will participate on the session “The Economics of Biosimilars: Considerations for Market Access, Sustainable Pricing and Reimbursement Policies.”